Christopher K Hopson

US Patent:

20130156779, Jun 20, 2013

Filed:

Sep 2, 2011

Appl. No.:

13/639918

Inventors:

Neil James Clarke - Stevenage, GB
Kyung Oh Johanson - King of Prussia PA, US
Zdenka Ludmila Jonak - King of Prussia PA, US
Alexander H. Taylor - King of Prussia PA, US
Christopher B. Hopson - Collegeville PA, US
Stephen H. Trulli - King of Prussia PA, US
Zdenka Haskova - King of Prussia PA, US
Judithann M. Lee - King of Prussia PA, US
John R. White - King of Prussia PA, US
Yu Xue - King of Prussia PA, US

International Classification:

C07K 16/28

US Classification:

4241391, 5303879, 5303873, 536 2353, 4353201, 435331, 435 696

Abstract:

The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.

US Patent:

20210155903, May 27, 2021

Filed:

Feb 5, 2021

Appl. No.:

17/168551

Inventors:

- Brentford Middlesex, GB
Christopher B. HOPSON - Collegeville PA, US

International Classification:

C12N 5/0783
C07K 16/28
A61P 35/00
A61K 38/17
A61K 45/06

Abstract:

Methods for increasing expression of at least one co-stimulatory and/or co-inhibitory receptor on a T cell comprising contacting said T cell with an anti-CTLA4 antibody are provided. In one aspect the co-stimulatory and/or co-inhibitory receptor is selected from the group of: PD-1, OX40, ICOS, CD137, TIM3, and LAG3. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-CTLA antibody and at least one additional agent directed to at least one co-stimulatory and/or co-inhibitory receptor to said human. In one aspect, the agent is directed to at least one co-stimulatory and/or co-inhibitory receptor selected from the group of: PD-1, OX40, ICOS, CD137 (4-1BB), TIM3, and LAG3.

US Patent:

20200190194, Jun 18, 2020

Filed:

Jun 8, 2018

Appl. No.:

16/620627

Inventors:

- BRENTFORD, GB
Christopher B. HOPSON - Collegeville PA, US
Patrick A. MAYES - Devon PA, US
Sapna YADA VILLI - Collegeville PA, US

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The present invention provides methods of treating cancer in a patient in need thereof, the method comprising administering to the patient an effective amount of an agent directed to human ICOS and an effective amount of an agent directed to human PD1 or human PD-L1 sequentially. The present invention also provides an anti-ICOS antibody or antigen binding fragment thereof and an anti-PD1 antibody or antigen binding fragment thereof for sequential use in treating cancer in a human in need thereof. The present invention provides an anti-ICOS antibody or antigen binding fragment thereof and an anti-PD-L1 antibody or antigen binding fragment thereof for sequential use in treating cancer in a human in need thereof.

US Patent:

20180230431, Aug 16, 2018

Filed:

Aug 4, 2016

Appl. No.:

15/749984

Inventors:

- Brentford, Middlesex, GB
Christopher B. HOPSON - Collegeville PA, US

International Classification:

C12N 5/0783
A61K 45/06
C07K 16/28
A61P 35/00
A61K 38/17

Abstract:

The present invention provides methods for increasing expression of at least one co-stimulatory and/or co-inhibitory receptor on a T cell comprising contacting said T cell with an anti-CTLA4 antibody. In one aspect the co-stimulatory and/or co-inhibitory receptor is selected from the group of: PD-1, OX40, ICOS, CD137, TIM3, and LAG3. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-CTLA antibody and at least one additional agent directed to at least one co-stimulatory and/or co-inhibitory receptor to said human. In one aspect, the agent is directed to at least one co-stimulatory and/or co-inhibitory receptor selected from the group of: PD-1, OX40, ICOS, CD137 (4-1BB), TIM3, and LAG3.